

Das Blutdepot in der Einrichtung der Krankenversorgung: Struktur- , Prozess- und Ergebnisqualität

1. Walther-Wenke G, Zeiler T. Blutdepots in Einrichtungen der Krankenversorgung – Rechtskonforme Organisation und qualitätsgesicherter Betrieb. Hämotherapie 24/2015,6-13
2. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie), www.baek.de
3. Gesetz über den Verkehr mit Arzneimitteln (AMG), www.gesetze-im-internet.de
4. Gesetz zur Regelung des Transfusionswesens (TFG), www.gesetze-im-internet.de
5. Arzneimittel- und Wirkstoffherstellungsverordnung (AMWHV), www.gesetze-im-internet.de
6. Berichte zur Meldung nach § 21 TFG, www.pei.de
7. Unfallverhütungsvorschrift DGUV Vorschrift 3, www.dguv.de

Rekombinante Blutgruppenproteine: Neue Möglichkeiten in der Antikörperdiagnostik

1. Bolton-Maggs PH, Cohen H: Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. *British journal of haematology*. 2013;163: 303-14.
2. Seltsam A, Wagner FF, Salama A, Flegel WA: Antibodies to high-frequency antigens may decrease the quality of transfusion support: an observational study. *Transfusion*. 2003;43: 1563-6.
3. Reid ME, Lomas-Francis C, Olsson ML: Blood group antigen factsbook. 3rd ed. San Diego, CA: Academic Press, 2012.
4. Ridgwell K, Dixey J, Scott ML: Production of soluble recombinant proteins with Kell, Duffy and Lutheran blood group antigen activity, and their use in screening human sera for Kell, Duffy and Lutheran antibodies. *Transfusion medicine*. 2007;17: 384-94.
5. Seltsam A, Blasczyk R: Recombinant blood group proteins for use in antibody screening and identification tests. *Curr Opin Hematol*. 2009;16: 473-9.
6. Seltsam A, Wagner F, Lambert M, Bullock T, Thornton N, Scharberg EA, Grueger D, Schneeweiss C, Blasczyk R: Recombinant blood group proteins facilitate the detection of alloantibodies to high-prevalence antigens and reveal underlying antibodies: results of an international study. *Transfusion*. 2014;54: 1823-30.
7. Daniels GL, Green CA, Powell RM, Ward T: Hemagglutination inhibition of Cromer blood group antibodies with soluble recombinant decay-accelerating factor. *Transfusion*. 1998;38: 332-6.
8. Moulds JM, Rowe KE: Neutralization of Knops system antibodies using soluble complement receptor 1. *Transfusion*. 1996;36: 517-20.
9. Seltsam A, Agaylan A, Grueger D, Meyer O, Blasczyk R, Salama A: Rapid detection of JMH antibodies with recombinant Sema7A (CD108) protein and the particle gel immunoassay. *Transfusion*. 2008;48: 1151-5.
10. Seltsam A, Agaylan A, Grueger D, Meyer O, Blasczyk R, Salama A: Rapid detection of anti-Lu(b) with recombinant Lu(b) protein and the particle gel immunoassay. *Transfusion*. 2008;48: 731-4.
11. Seltsam A, Grueger D, Blasczyk R, Flegel WA: Easy identification of antibodies to high-prevalence Scianna antigens and detection of admixed alloantibodies using soluble recombinant Scianna protein. *Transfusion*. 2009;49: 2090-6.
12. Seltsam A, Grüger D, Blasczyk R: Prokaryotic versus eukaryotic recombinant Lutheran blood group protein for antibody identification. *Transfusion*. 2007;47: 1630-6.
13. Seltsam A, Strigens S, Levene C, Yahalom V, Moulds M, Moulds JJ, Hustinx H, Weisbach V, Figueroa D, Bade-Doeding C, DeLuca DS, Blasczyk R: The molecular diversity of Sema7A, the semaphorin that carries the JMH blood group antigens. *Transfusion*. 2007;47: 133-46.
14. Telen MJ, Rao N, Udani M, Thompson ES, Kaufman RM, Lublin DM: Molecular mapping of the Cromer blood group Cra and Tca epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology. *Blood*. 1994;84: 3205-11.
15. Yazdanbakhsh K, Oyen R, Yu Q, Lee S, Antoniou M, Chaudhuri A, Reid ME: High-level, stable expression of blood group antigens in a heterologous system. *Am J Hematol*. 2000;63: 114-24.
16. Heuft H-G, Dahm A, Lanz S, Wille G, Graf M, Schneeweiss C, Blasczyk R: Soluble recombinant blood group proteins for red blood cell antibody identification. *Transfus Med Hemother*. 2014;41(suppl 1): 18.
17. Heuft HG, Genth R, Wittmann G, Salama A: Alloantibodies directed against high-frequency red blood cell antigens. *Infusionsmed Transfusionsmed*. 1999;26: 234-9.
18. Heuft H-G: Stellenwert löslicher rekombinanter Blutgruppenproteine im immunhämatologischen Labor. *Transfusionsmedizin*. 2015;5: 74-9.

Immunhämatologische Besonderheiten bei Personen mit Migrationshintergrund

1. Reid, Lomas-Francis Blood Group Antigen Facts Book
2. AlSuhaibani ES, Kizilbash NA, Afshan K and Malik S. Distribution and clinal trends of the ABO and Rh genes in select Middle Eastern countries. Genet. Mol. Res. 14 (3): 10729-10742 (2015)
3. [2] Abdelaal MA, Anyaegbu CC, al Sobhi EM, al Baz NM, Hodan KBlood group phenotype distribution in Saudi Arabs. Afr J Med Med Sci. 1999 Sep-Dec;28(3-4):133-5.
4. Mazieres S, Temory SA, Vasseur H, Gallian P, Di Cristofaro J and Chiaroni J. Blood group typing in five Afghan populations in the North Hindu-Kush region: implications for blood transfusion practice. Transfusion Medicine, 2013, 23, 167–174
5. Kalaydjieva L, Gresham D and Calafell F. Genetic studies of the Roma (Gypsies): a review. BMC Medical Genetics (2001) 2:5
6. Noizat-Pirenne F, Verdier M, Lejealle A, Mercadier A, Bonin P, Peltier-Pujol F, Fialaire-Legendre A, Tournamille C, Bierling P, Ansart-Pirenne H. Weak D phenotypes and transfusion safety: where do we stand in daily practice? Transfusion. 2007 Sep;47(9):

Plättchenlysat (PL) aus Thrombozytenkonzentraten als pharmazeutischer Hilfsstoff im Sinne einer optimierten Verwendung von Blutprodukten

1. Bieback K, Hecker A, Kocaomer A et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. *Stem Cells*. 2009;27(9):2331-2341.
2. Fekete N, Gadelorge M, Furst D et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. *Cytotherapy*. 2012;14(5):540-554.
3. Fekete N, Rojewski MT, Lotfi R, Schrezenmeier H. Essential Components for Ex Vivo Proliferation of Mesenchymal Stromal Cells. *Tissue Eng Part C.Methods*. 2013
4. Schallmoser K, Bartmann C, Rohde E et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. *Transfusion*. 2007;47(8):1436-1446.
5. Walenda G, Hemeda H, Schneider RK et al. Human platelet lysate gel provides a novel three dimensional-matrix for enhanced culture expansion of mesenchymal stromal cells. *Tissue Eng Part C.Methods*. 2012;18(12):924-934.
6. Rizzo C, Vetro R, Vetro A et al. The role of platelet gel in osteoarticular injuries of young and old patients. *Immun.Ageing*. 2014;11(1):21-0021.
7. Burnouf T, Goubran HA, Chen TM et al. Blood-derived biomaterials and platelet growth factors in regenerative medicine. *Blood Rev*. 2013;27(2):77-89.

Neues aus der Rubrik „Was tun wir bei....?“

1. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten – Herausgegeben von der Bundesärztekammer auf Empfehlung ihres wissenschaftlichen Beirats; vierte, überarbeitete Auflage; Deutscher Ärzteverlag Köln 2014.
2. Dienstanweisung für die klinische Anwendung von Blut und Blutprodukten im Klinikum der J. W. Goethe-Universität Frankfurt/Main; Version 3; 2013.

Patient Blood Management

1. Koch CG, Li L, Sun Z, Hixson ED, Tang A, Phillips SC, Blackstone EH, Henderson JM: Hospital-acquired anemia: Prevalence, outcomes, and healthcare implications. *J Hosp Med* 2013, 8(9):506-512.
2. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ: The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. *Critical care medicine* 2004, 32(1):39-52.
3. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellmann A, Nollet G, Peres-Bota D, Investigators ABC: Anemia and blood transfusion in critically ill patients. *JAMA* 2002, 288(12):1499-1507.
4. Widness JA, Madan A, Grindeanu LA, Zimmerman MB, Wong DK, Stevenson DK: Reduction in red blood cell transfusions among preterm infants: results of a randomized trial with an in-line blood gas and chemistry monitor. *Pediatrics* 2005, 115(5):1299-1306.